Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Ottawa
$27,000.00
Engineering Parkin for mitochondrial targeting as a therapeutic strategy to rescue mitophagy in Parkinson’s disease
FY 2025-26
Summary
Parkinson’s disease (PD) is a progressive neurodegenerative disease affecting millions worldwide, leading to tremors, cognitive decline, and the death of dopaminergic neurons. A key contributing factor to PD pathogenesis is mitochondrial dysfunction, including the inability to selectively clear damaged mitochondria or mitophagy. Parkin is an E3 ubiquitin ligase encoded by the PRKN gene that mediates mitophagy by ubiquitinating outer mitochondrial membrane (OMM) proteins and likely sequesters reactive oxygen species (ROS) to reduce oxidative stress. Unfortunately, PRKN is mutated in the majority of early-onset PD cases. These mutations result in the accumulation of dysfunctional mitochondria and neuronal death, leading to PD symptoms. To address this, Parkin will be engineered to enhance its mitochondrial localization and function. Using genetic code expansion (GCE), non-canonical amino acids (ncAAs) will be incorporated into both Parkin and a synthetic peptide, enabling site-specific conjugation with ncAA-modified cell-penetrating peptides (CPPs) and mitochondrial targeting sequences (MTSs) via copper-free click chemistry. This will facilitate Parkin’s cellular uptake and mitochondrial localization. These modified Parkin mutants will be tested in well-characterized PD cell and mouse models to evaluate their ability to rescue mitophagy. This approach has the potential to improve therapeutic targeting of PD, especially early-onset PD where conventional PD treatments are ineffective.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
582684
Name
Ko Ashley
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Engineering Parkin for mitochondrial targeting as a therapeutic strategy to rescue mitophagy in Parkinson’s disease
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Biological Therapeutics; Chemical Biology; Click Chemistry; Genetic Code Expansion; Mitochondrial Homeostasis; Neurodegeneration; Oxidative Stress; Parkinson'S Disease; Protein Engineering
Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disease affecting millions worldwide, leading to tremors, cognitive decline, and the death of dopaminergic neurons. A key contributing factor to PD pathogenesis is mitochondrial dysfunction, including the inability to selectively clear damaged mitochondria or mitophagy. Parkin is an E3 ubiquitin ligase encoded by the PRKN gene that mediates mitophagy by ubiquitinating outer mitochondrial membrane (OMM) proteins and likely sequesters reactive oxygen species (ROS) to reduce oxidative stress. Unfortunately, PRKN is mutated in the majority of early-onset PD cases. These mutations result in the accumulation of dysfunctional mitochondria and neuronal death, leading to PD symptoms. To address this, Parkin will be engineered to enhance its mitochondrial localization and function. Using genetic code expansion (GCE), non-canonical amino acids (ncAAs) will be incorporated into both Parkin and a synthetic peptide, enabling site-specific conjugation with ncAA-modified cell-penetrating peptides (CPPs) and mitochondrial targeting sequences (MTSs) via copper-free click chemistry. This will facilitate Parkin’s cellular uptake and mitochondrial localization. These modified Parkin mutants will be tested in well-characterized PD cell and mouse models to evaluate their ability to rescue mitophagy. This approach has the potential to improve therapeutic targeting of PD, especially early-onset PD where conventional PD treatments are ineffective.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ko, Ashley
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~